Literature DB >> 22310931

Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor.

Christiane Sahm1, Kurt Schönfeld, Winfried S Wels.   

Abstract

Natural killer (NK) cells hold promise for adoptive cancer immunotherapy but are dependent on cytokines such as interleukin (IL)-2 for growth and cytotoxicity. Here, we investigated the consequences of ectopic expression of IL-15 in human NK cells. IL-2 and IL-15 belong to the common γ chain family of cytokines and have overlapping activities. Transduction of clinically applicable NK-92 cells with lentiviral vectors encoding human IL-15 resulted in predominantly intracellular expression of the cytokine, and STAT5 activation, proliferation and cytotoxicity of the producer cells in the absence of IL-2. Growth of non-transduced bystander cells was not supported, allowing rapid enrichment of gene-modified cells solely by IL-2 withdrawal. This was also the case upon transduction of NK-92 and NKL cells with a bicistronic lentiviral vector encoding IL-15 and a chimeric antigen receptor (CAR) targeting the pancarcinoma antigen EpCAM. Effector cells co-expressing CAR and IL-15 continued to proliferate in the absence of exogenous cytokines and displayed high and selective cell-killing activity against EpCAM-expressing breast carcinoma cells that were resistant to the natural cytotoxicity of unmodified NK cells. This strategy facilitates rapid isolation and continuous expansion of retargeted NK cells and may extend their potential clinical utility.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22310931     DOI: 10.1007/s00262-012-1212-x

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  71 in total

Review 1.  Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.

Authors:  Sayed Shahabuddin Hoseini; Nai-Kong V Cheung
Journal:  Cancer Lett       Date:  2017-04-17       Impact factor: 8.679

Review 2.  Engineering Natural Killer Cells for Cancer Immunotherapy.

Authors:  Katayoun Rezvani; Rayne Rouce; Enli Liu; Elizabeth Shpall
Journal:  Mol Ther       Date:  2017-06-28       Impact factor: 11.454

3.  Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers.

Authors:  Elizabeth L Siegler; Yu Jeong Kim; Xianhui Chen; Natnaree Siriwon; John Mac; Jennifer A Rohrs; Paul D Bryson; Pin Wang
Journal:  Mol Ther       Date:  2017-08-19       Impact factor: 11.454

4.  Potential Cancer Prevention and Treatment by Silencing the Killer Cell Immunoglobulin-like Receptor Gene in Natural Killer Cells Derived from Induced Pluripotent Stem Cells.

Authors:  Yunlong Qin; Christina Hutson; Xianfu Wu; Jingyao Xu; Darin Carroll
Journal:  Enliven J Stem Cell Res Regen Med       Date:  2016-07-06

5.  3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids.

Authors:  Theresa E Schnalzger; Marnix Hp de Groot; Congcong Zhang; Mohammed H Mosa; Birgitta E Michels; Jasmin Röder; Tahmineh Darvishi; Winfried S Wels; Henner F Farin
Journal:  EMBO J       Date:  2019-04-29       Impact factor: 11.598

Review 6.  Leveraging natural killer cells for cancer immunotherapy.

Authors:  Steven K Grossenbacher; Ethan G Aguilar; William J Murphy
Journal:  Immunotherapy       Date:  2017-05       Impact factor: 4.196

Review 7.  NK cells and cancer: you can teach innate cells new tricks.

Authors:  Maelig G Morvan; Lewis L Lanier
Journal:  Nat Rev Cancer       Date:  2016-01       Impact factor: 60.716

Review 8.  Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.

Authors:  Dominique Bollino; Tonya J Webb
Journal:  Transl Res       Date:  2017-06-09       Impact factor: 7.012

9.  Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.

Authors:  E Liu; Y Tong; G Dotti; H Shaim; B Savoldo; M Mukherjee; J Orange; X Wan; X Lu; A Reynolds; M Gagea; P Banerjee; R Cai; M H Bdaiwi; R Basar; M Muftuoglu; L Li; D Marin; W Wierda; M Keating; R Champlin; E Shpall; K Rezvani
Journal:  Leukemia       Date:  2017-07-20       Impact factor: 11.528

10.  High-throughput screening for identification of inhibitors of EpCAM-dependent growth of hepatocellular carcinoma cells.

Authors:  Curtis J Henrich; Anuradha Budhu; Zhipeng Yu; Jason R Evans; Ekaterina I Goncharova; Tanya T Ransom; Xin W Wang; James B McMahon
Journal:  Chem Biol Drug Des       Date:  2013-08       Impact factor: 2.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.